Low prevalence of inhibitor antibodies in the Canadian haemophilia population

Haemophilia

Volumn 18, Issue 3, 2012, Pages

  Webert, K E ^a   Rivard, G E ^b   Teitel, J ^c   Carcao, M ^d   Lillicrap, D ^e   St Louis, J ^b,f   Walker, I R ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Epidemiology; Factor IX; Factor VIII; Haemophilia; Inhibitors; Prevalence

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CHILD; CLINICAL CLASSIFICATION; DISEASE SEVERITY; FOLLOW UP; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; INFANT; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; VALIDATION STUDY;

ADOLESCENT; ADULT; CANADA; CHILD; CHILD, PRESCHOOL; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; ISOANTIBODIES; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84860342463     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02694.x     Document Type: Article

References (16)

1. Teitel J. Inhibitor economics. Semin Hematol 2006; 43(2 Suppl 4): S14-7.
2. Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost 2004; 2: 1082-95.
3. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
4. Kreuz W, Ettingshausen CE, Auerswald G et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
5. Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia 2006; 12(Suppl 6): 23-8; discussion 28-9.
6. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
7. Canadian Hemophilia Registry. A Project of the Association of Hemophilia Clinic Directors of Canada. Available at: Accessed May 20, 2009.
8. Walker I, Pai M, Akabutu J et al. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995; 35: 548-51.
9. Association of Hemophilia Clinic Directors of Canada. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. CMAJ 1995; 153: 19-25.
10. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
11. Darby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
12. Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briet E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123: 823-7.
13. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7.
14. Mannucci P, Schutgens REG, Santagostino E, Mauser-Bunschoten E. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009; 114: 5256-63.
15. Statistics Canada. Canadian Census 2006. Available at: Accessed June 15, 2011.
16. Rubinger M, Lillicrap D, Rivard GE et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14: 281-6.